Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) ToolkitMarch 5, 2024
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of DirectorsDecember 1, 2023
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceNovember 16, 2023